Q1 2026 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Reduced by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Tuesday, September 17th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $2.75 per share for the quarter, down from their previous estimate of $2.77. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.47 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2026 earnings at $3.20 EPS and FY2026 earnings at $12.43 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) earnings per share.

Several other brokerages have also issued reports on SRPT. Citigroup cut their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. UBS Group lifted their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday. Piper Sandler dropped their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Bank of America lifted their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research note on Friday, June 21st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $152.00 price target on shares of Sarepta Therapeutics in a research note on Friday. Three analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $187.39.

Sarepta Therapeutics Stock Up 0.1 %

NASDAQ:SRPT opened at $127.21 on Friday. The business’s fifty day moving average price is $137.76 and its 200 day moving average price is $132.57. The firm has a market capitalization of $12.02 billion, a price-to-earnings ratio of 1,145.09 and a beta of 0.81. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05.

Insider Transactions at Sarepta Therapeutics

In other news, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,801 shares of company stock worth $8,399,586. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Riggs Asset Managment Co. Inc. grew its stake in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares during the period. GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the period. EP Wealth Advisors LLC grew its stake in shares of Sarepta Therapeutics by 2.1% in the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 103 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in shares of Sarepta Therapeutics by 1.9% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares during the period. Finally, WCM Investment Management LLC grew its stake in shares of Sarepta Therapeutics by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.